PHILADELPHIA - James Shorter, PhD, assistant professor of Biochemistry and Biophysics has received a 2009 Ellison Medical Foundation New Scholar Award in Aging. New Scholar candidates are investigators who are nominated by U.S. medical institutions and universities for their outstanding promise in aging research. The award provides funding up to $100,000 per year for a four year period to a maximum of 25 scholars.
“I'm delighted, but also a little bit surprised to have won this award. When you consider the quality of the other awardees, it’s clearly a great privilege. The Ellison New Scholar Award in Aging is also very special because I am now following in the footsteps of some very cool scientists like Ana Maria Cuervo and David Sinclair,” says Shorter.
New Scholar awards provide support for newly independent investigators, beginning in the first three years after their postdoctoral training. These awards allow young scientists to staff their laboratories, collect preliminary data, and organize research programs of sufficient momentum to obtain ongoing support from other sources.
Shorter studies how baker’s yeast can be applied to the study of such lethal nerve degeneration disorders as Alzheimer's disease and amyotrophic lateral sclerosis (ALS), which are associated with the clumping of specific proteins. Yeast expresses a protein called Hsp104, which is able to dissolve and reactivate misfolded proteins that are trapped in toxic protein clumps.
“We aim to engineer Hsp104 to work more effectively in this de-clumping process,” explains Shorter. “We are focusing on two specific proteins that form toxic assemblies in Alzheimer's disease and ALS.”
Shorter received his undergraduate degree from Keble College, University of Oxford and his PhD from University College London.
For more information, please visit the Shorter Lab website.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.